Literature DB >> 26981845

Overcoming challenges of treating inflammatory bowel disease in pregnancy.

Jill K J Gaidos1, Sunanda V Kane2.   

Abstract

Inflammatory bowel disease (IBD) is frequently diagnosed before or during the peak reproductive years. Overall management of inflammatory bowel disease is becoming more complex given the nuances involved with multiple mechanisms of action of the current treatment and need for therapeutic monitoring for safety and efficacy; another layer of complexity is added in the setting of a pregnancy. In this review, we have identified several key challenges that health care providers face when caring for patients with IBD during pregnancy. The goal of this review is to provide the most up-to-date evidence and provide our expert recommendations so that providers can more comfortably address patients' questions about pregnancy in IBD and the associated risks as well as optimize their care to ensure the best outcomes possible.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; adalimumab; certolizumab pegol; infliximab; natalizumab; pregnancy; ulcerative colitis; vedolizumab

Mesh:

Year:  2016        PMID: 26981845     DOI: 10.1586/1744666X.2016.1166958

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  2 in total

1.  Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review.

Authors:  Birgit Terjung; Renate Schmelz; Robert Ehehalt; Jochen Klaus; Jana Knop; Sabine Schwind; Thomas Wilke; Andreas Stallmach
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

Review 2.  Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy.

Authors:  Noritaka Takatsu; Takashi Hisabe; Daijiro Higashi; Toshiharu Ueki; Toshiyuki Matsui
Journal:  Core Evid       Date:  2020-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.